Canaccord analyst Sumant Kulkarni lowered the firm’s price target on Clene (CLNN) to $83 from $86 and keeps a Buy rating on the shares.

Water, a molecule essential for life, has unusual properties - known as anomalies - that define its behaviour. However, there are still many enigmas ...

Zac Brown Band's John Driskell Hopkins is turning his battle with ALS into a mission to help others: "When you're given a ...

Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential ...

Restaurateur Al Biernat passed away on Wednesday, November 13, after being diagnosed with amyotrophic lateral sclerosis, also ...

The National Institute of Aging awarded a $7.3 million research grant for the study of NU-9 as a treatment for ...

ALS is a neurodegenerative disease that progressively paralyzes individuals as the brain loses the ability to communicate with the muscles. People living with ALS often experience a swift decline in ...

Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential ...

Target enrollment in the chronic cohort of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury ...

The Oak Ridge Boys are on their “American Made” farewell tour and the group seems sincere about saying goodbye to the ...

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis.

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September and, according to ...